ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

Åãͬ×ÅCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨µÄÉú³¤£¬£¬£¬£¬£¬£¬ÏÖÔÚѪҺÖ×ÁöÒѾ­²»ÔÙÊÇÎÞ½âµÄÄÑÌ⣬£¬£¬£¬£¬£¬ÏÖÔÚÒѾ­ÓжàÖÖCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨¿ÉÒÔÔÚѪҺÖ×ÁöµÄÖÎÁÆÖеִï90%ÒÔÉϵĿ͹ۻº½âÂÊ£¬£¬£¬£¬£¬£¬²¢ÇÒ´Óºã¾ÃµÄÖÎÁÆÊý¾ÝÀ´¿´£¬£¬£¬£¬£¬£¬»¼Õß×ÜÌåÉúÑÄÂÊÒ²¿ÉÒÔµÖ´ï44%£¨4ÄêÉúÑÄÆÚ£©£¬£¬£¬£¬£¬£¬Í¬Ê±×ÝÈ»ÊÇÖ×Áö¸´·¢ÁË£¬£¬£¬£¬£¬£¬Ò²¿ÉÒÔÔٴνÓÊÜCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆ£¬£¬£¬£¬£¬£¬ÕâÒâζ×ÅCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨ÒѾ­´ó´ó½µµÍÁËѪҺÖ×ÁöµÄΣº¦¡£¡£¡£¡£¡£¡£¡£¡£

CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¹¥»÷Ö×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¨Í¼Æ¬ÈªÔ´£ºÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£©

¿ÉÊÇÕûÌåÀ´Ëµ£¬£¬£¬£¬£¬£¬ÑªÒºÖ×ÁöÕ¼±ÈÔÚËùÓÐÖ×ÁöÖв¢²»¸ß£¬£¬£¬£¬£¬£¬´ó´ó¶¼Ö×Áö»¼Õ߶¼ÊÇʵÌåÁö¡£¡£¡£¡£¡£¡£¡£¡£ÒÔÊÇ£¬£¬£¬£¬£¬£¬CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÊÇ·ñÄÜÓÐÓõع¥¿ËʵÌåÖ×Áö²ÅÊÇÖ×ÁöÃâÒßÖÎÁƵÄÒªº¦¡£¡£¡£¡£¡£¡£¡£¡£¹¥¿ËʵÌåÖ×Áö×î½¹µãµÄÎÊÌâÊÇÕÒµ½ÌØÒìÐԵİеãÏ¢Õù³ýÖ×Áö΢ÇéÐιØÓÚCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÃâÒßÒÖÖÆ£¬£¬£¬£¬£¬£¬ÄÇôµ½ÕâÀïÎÒÃǾͲ»µÃ²»Ìáµ½PD-1/PD-L1×÷ÓÃÖá——ËüÃÇÕýÊÇÖ÷Ô×Ö×ÁöÒýÆðTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÃâÒßÒÖÖƵÄÖ÷Ҫ;¾¶¡£¡£¡£¡£¡£¡£¡£¡£

ÓëCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÁÆ·¨²î±ðµÄÊÇ£¬£¬£¬£¬£¬£¬ PD-1/PD-L1ÒÖÖƼÁµÄ×÷ÓûúÖÆÊÇ×è¶ÏPD-1ÓëPD-L1µÄÏ໥×÷Ó㬣¬£¬£¬£¬£¬´Ó¶øɨ³ýÀ´×ÔÖ×ÁöµÄPD-L1¶ÔTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÒÖÖÆ¡£¡£¡£¡£¡£¡£¡£¡£¿ÉÊÇÕâЩÒÖÖƼÁÊÇ·ñÄܽøÈëÖ×Áö΢ÇéÐÎÊ©Õ¹×÷ÓÃÊÇÆäÖÎÁƳɰܵÄÒªº¦£¬£¬£¬£¬£¬£¬¶ø¸ßŨ¶È»òÍŽáÓ¦ÓÃÓֻᵼÖÂÈ«ÉíµÄ¸±×÷ÓÃÔöÌí¡£¡£¡£¡£¡£¡£¡£¡£ÊÇ·ñ¿ÉʹÓñí´ïPD-1¿¹ÌåµÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬ÒÔʵÏÖPD-1¿¹ÌåÔÚ¾Ö²¿ÐγɸßŨ¶È£¬£¬£¬£¬£¬£¬¶øɨ³ýÖ×Áö΢ÇéÐÎÒÖÖÆÄØ£¿£¿£¿£¿£¿£¿£¿

2ÔÂ18ÈÕ£¬£¬£¬£¬£¬£¬¡¶BMJ¡·£¨¡¶Ó¢¹úÒ½Ò©ÔÓÖ¾¡·£©ÆìϵĹú¼ÊÒ»Á÷ѧÊõÆÚ¿¯¡¶Journal for ImmunoTherapy of Cancer¡·£¨¡¶°©Ö¢ÃâÒßÖÎÁÆÔÓÖ¾¡·£©£¨IF=10.252£©ÔÓÖ¾ÉϽÒÏþµÄÎÊÌâÃûΪ“αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib”ÁÙ´²°¸Àý±¨¸æ£¬£¬£¬£¬£¬£¬»Ø¸²ÁËÕâÒ»ÎÊÌâ¡£¡£¡£¡£¡£¡£¡£¡£

ͼƬȪԴ£º¡¶Journal for ImmunoTherapy of Cancer¡·¹ÙÍø

¸ÃƪÎÄÕÂÒ²Êǹú¼ÊÉϵÚһƪ¹ØÓÚÓÃCAR-T×ÔÉø͸PD-1¿¹ÌåÖÎÁÆʵÌåÖ×ÁöµÄÁÙ´²ÎÄÕ£¬£¬£¬£¬£¬£¬Í¬Ê±Ò²ÊÇÉϺ£ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÍŶӴòÔìµÄ°×ÔóTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÊÖÒÕÊ×´ÎÔÚʵÌåÖ×ÁöÁÙ´²»ñµÃÏÔ×ÅÁÆЧµÄ°¸Àý¡£¡£¡£¡£¡£¡£¡£¡£

½ÓÊÜÖÎÁƵÄÊÇÒ»Ãû54ËêµÄÍíÆÚÂѳ²½¬ÒºÐÔÏÙ°©Å®ÐÔ»¼Õߣ¬£¬£¬£¬£¬£¬ÔÚÇ°ÆÚµÄÃâÒßѧ¼ì²éÊý¾ÝÖÐÏÔʾ£º

ÑôÐÔµÄÖ¸±êÓУºCK7(+), CA125(+), WT-1(+), EMA(+), CAM5.2 (+), ER(+), PR(+++), calretinin (partial +), p53(+++), Ki67(60%), CD34(blood vessel +)£»£»£»£»£»

ÒõÐÔÖ¸±êΪ£ºHer2, CK20, CA19-9, ²¨ÐÎÂÑ°×, CEA, and HBME-1¡£¡£¡£¡£¡£¡£¡£¡£

»¼ÕßÊ×ÏȽÓÊÜ×Ïɼ´¼ÍŽá˳²¬»¯ÁÆ£¬£¬£¬£¬£¬£¬¹²8´Î¡£¡£¡£¡£¡£¡£¡£¡£ºó¾­¼ªÎ÷Ëû±õ¼Ó°ÂɳÀû²¬ËĸöÖÜÆÚÖÎÁÆ£¬£¬£¬£¬£¬£¬Ê¹¼²²¡ÎȹÌ¡£¡£¡£¡£¡£¡£¡£¡£È»¶øµ½2017Äê8Ô£¬£¬£¬£¬£¬£¬¸Î²¿·ºÆðÐÂС²¡±ä£¬£¬£¬£¬£¬£¬µ«2018Äê3Ô²¡±äÀ©´ó£¬£¬£¬£¬£¬£¬Ëæ½ÓÊÜ°¢ÅÁÌæÄáÖÎÁƺ󼲲¡ÔÙ´ÎÎȹÌ¡£¡£¡£¡£¡£¡£¡£¡£2018Äê10ÔÂÖ×Áö¸´·¢Ê±£¬£¬£¬£¬£¬£¬¾­ÓÉÃâÒßѧ¼ì²éÆÀ¹À£¬£¬£¬£¬£¬£¬»¼ÕßתÒÆÔîºÍÔ­·¢Ôî¾ù±í´ï¼äƤËØ£¬£¬£¬£¬£¬£¬ÇкÏÈë×éÌõ¼þ£¬£¬£¬£¬£¬£¬»¼ÕßÇ©ÊðÖªÇéÔÞ³ÉÊéºóÓÚ2018Äê12Ô½ÓÊÜPD-1-meso CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ê×´ÎÖÎÁÆ£¬£¬£¬£¬£¬£¬2019Äê1Ô½ÓÊܵڶþ´ÎÊä×¢¡£¡£¡£¡£¡£¡£¡£¡£

»¼Õß½ÓÊÜÖÎÁÆÖÜÆÚ¼°Ó°Ïñѧ×ÊÁϱÈÕÕ£¬£¬£¬£¬£¬£¬¿É¼ûÖÎÁƺóÖ×ÁöÏÔ×ÅËõС£¡£¡£¡£¡£¡£¡£¡£¨Í¼Æ¬ÈªÔ´£º²Î¿¼×ÊÁÏ1£©

±¾´ÎʹÓõÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ô­ÖÊÁÏȪԴÓÚ»¼Õß×ÔÉíµÄTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬ÔÚÖƱ¸Àú³ÌÖÐʹÓõÄÊǷDz¡¶¾ÔØÌåÖƱ¸ÊÖÒÕ¡£¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»ØÊäPD-1-meso CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ºó£¬£¬£¬£¬£¬£¬»¼ÕßѪҺ²»µ«CAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÊýÄ¿»ñµÃÁËÀ©Ôö£¬£¬£¬£¬£¬£¬²¢ÇÒ×ÔÉíµÄCD8+TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄ»îÐÔÒ²»ñµÃÁËÔöÇ¿£¬£¬£¬£¬£¬£¬ÕâÅú×¢»ØÊä½øÈËÌåµÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÒѾ­×îÏÈ·¢Æôº½ÌåÄÚµÄÃâÒßÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøվΧ½ËÖ×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬´Ó¶øÊ©Õ¹¸üºÃµÄ¿¹Ö×ÁöЧ¹û¡£¡£¡£¡£¡£¡£¡£¡£

ÍŽáÁÆ·¨µÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖƱ¸¡¢»ØÊäºÍ¼ì²âʱ¼ä±í¡¢PD-1¿¹ÌåÒÔ¼°ÌåÄÚÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Òò×ÓÖÎÁÆÇ°ºóת±ä£¨Í¼Æ¬ÈªÔ´£º²Î¿¼×ÊÁÏ1£©

ÔÚÒÔÍùµÄÖÎÁÆÇéÐÎÖУ¬£¬£¬£¬£¬£¬ÃâÒß×éºÏËäÈ»»áÔöÌíÖÎÁÆЧ¹û£¬£¬£¬£¬£¬£¬¿ÉÊÇÒ²»áÔöÇ¿ÖÎÁƵĸ±×÷Ó㬣¬£¬£¬£¬£¬ÄÇôCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾×ÔÉø͸PD-1¿¹ÌåÊÇ·ñ»áÔöÌí¸±×÷Óõı¬·¢ÄØ£¿£¿£¿£¿£¿£¿£¿

±¾°¸Àý¼°ÆäËûÉÐ䱨µÀµÄ°¸Àý·¢Ã÷£¬£¬£¬£¬£¬£¬ÕâÖֶ๦ЧCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾²¢Ã»ÓÐÒýÆðµÄÏÔ×ŵIJ»Á¼·´Ó¦£¬£¬£¬£¬£¬£¬½ö·ºÆðÁ˸ßѪѹ1¼¶ºÍ·¦Á¦µÈÉÔ΢µÄ¸±×÷Óᣡ£¡£¡£¡£¡£¡£¡£ÎÒÃÇÍƲâPD-1¿¹Ìå¿ÉÄÜÍ£ÁôÔÚCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾°ÐÏòºÍÀ©ÔöµÄµØ·½£¬£¬£¬£¬£¬£¬Ð§¹û²»»áÔì³ÉÑÏÖز»Á¼·´Ó¦¡£¡£¡£¡£¡£¡£¡£¡£

±¾´ÎµÄÖÎÁÆ°¸Àý£¬£¬£¬£¬£¬£¬¸ü¾ßÓÐÒâÒåµÄÒ»µãÊǸ¶ÓëÁËCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¸ü¶àµÄ¹¦Ð§£º´Ó½ö½öÓÃÓÚ°ÐÏòɱÉËÖ×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬Äð³ÉÁË¿ÉÒÔЯ´ø¶àÖÖ¿¹Ìå´Ó¶ø¸Ä±äÖ×Áö΢ÇéÐβ¢¼¤»îÌåÄÚÔ­ÓеÄÃâÒßÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬£¬£¬ÅäºÏ¶Ô¿¹Ö×Áö£¬£¬£¬£¬£¬£¬ÌåÏÖÁË“Ö×Áö¾Ö²¿É±ÉË+ÐÞ¸´Ö×Áö¾Ö²¿ÃâÒß·´Ó¦”£¬£¬£¬£¬£¬£¬´Ó¶ø¸üºÃ¡¢¸ü³¤ÆÚµÄÊ©Õ¹¿¹Ö×Áö×÷Óᣡ£¡£¡£¡£¡£¡£¡£